您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > ML 218 hydrochloride
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
ML 218 hydrochloride
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
ML 218 hydrochloride图片
包装与价格:
包装价格(元)
10mg电议
50mg电议

产品介绍
ML 218 hydrochloride 是一种有效的、选择性的和具有口服活性的 T 型 Ca2+ 通道 (Cav3.1, Cav3.2, Cav3.3) 抑制剂,对 Cav3.2 和 Cav3.3 的 IC50 分别为 310 nM 和 270 nM。

Animal experiment:

Rats: ML218 is administered intravenously (IV) to rats via the jugular vein catheter in 20% DMSO/80% saline at a dose of 1 mg/kg and a dose volume of 1 mL/kg. Blood collections via the carotid artery are performed at predose, and at 2 min, 7 min, 15 min, 30 min, and 1 h, 2 h, 4 h, 7 h, and 24 h post dose. Samples are collected into chilled, EDTA-fortified tubes, and centrifuged for 10 min at 3000 rpm (4℃), and resulting plasma is aliquoted into 96-well plates for LC/MS/MS analysis. For oral exposure studies, measuring both systemic plasma and CNS tissue exposure, ML218 is administered (oral gavage) to fasted rats as suspensions in 10% Tween 80/0.5% methylcellulose at a dose of 10 mg/kg and in a dosing volume of 10 mL/kg; blood and whole brain samples are collected at 1.5 h post dose. Blood is collected into chilled, EDTA-fortified tubes, centrifuged for 10 min at 3000 rpm (4℃), and stored at –80 ℃ until LC/MS/MS analysis[1].

产品描述

ML218 is a selective T-type calcium channel inhibitor with IC50s of 270 and 310 nM for Cav3.3 and Cav3.2 in electrophysiology assay, respectively.

ML218 (CID 45115620) inhibits Cav3.1, Cav3.2, Cav3.3[1].

Electrophysiology studies in STN neurons demonstrate robust effects of ML218 on the inhibition of T-type calcium current, inhibition of low threshold spike, and rebound burst activity. ML218 was found to be orally efficacious in a dose-dependent manner in a preclinical Parkinson’s disease model, haloperidol-induced catalepsy, and comparable to clinically validated A2A antagonism[1]. ML218 reaches a peak cerebrospinal fluid concentration 1-2 hrs after s.c. administration. No effects of ML218 on cardiac rhythmicity is found in electrocardiographic studies. ML218 does not have antiparkinsonian effects in MPTP-treated parkinsonian monkeys, due at least in part, to the agent’s sedative effects[2].

References:
[1]. Xiang Z, et al. The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.
[2]. https://www.ncbi.nlm.nih.gov/pubmed/22368764